REG - OptiBiotix Health - Trading Update

OptiBiotix HealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260401:nRSA9382Ya&default-theme=true

RNS Number : 9382Y  OptiBiotix Health PLC  01 April 2026

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

Trading update

Strong period of growth and record start to 2026

 

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business
developing products which reduce hunger and food cravings, enhance the gut
microbiome, and sweet fibres as healthy sugar substitutes provides the
following unaudited trading update for the financial year ended 31 December
2025.

 

·    Sales orders up 33% to £1.34m including £212k of orders carried
forward for delivery in 2026

·    Revenue up 30% to £1.13m (2024: £870K)

·    Gross profit up 82% to £603K (2024: £331K)

·    Gross profit margin increased to 53% (2024: 38%)

·    Operating costs (including selling, R&D and patent costs but
excluding non-cash shared based payments) are stable at £2.6m (2024: £2.6m)

·    Cash balance of £1.03m (2024: £739k)

·    Holdings in ProBiotix Health Plc ("PBX") and SkinBioTherapeutics Plc
("SBTX") with an aggregate market value of £6.45m as of 31 December 2025.

·    Launch of SlimBiome® in Hydroxycut, which markets itself as the No.
1 selling weight loss supplement brand in the United States of America ("USA")

·    Signing of a distribution agreement with a well-known direct selling
weight management company with a first order received in H2 2025 with product
launch scheduled for H1 2026

·    Growing list of new customers in Asia with 17 products launched and
74 customer projects at various stages of development across six different
countries

·    Introduction of an optimised enzyme-based production process for
SweetBiotix that delivers much higher yields, delivers a purer and
better-tasting product, and reduces ingredient and production costs

 

Post period

·    Twenty-four metric tonnes (24mt) SlimBiome order from Meelung
Trading, Taiwan to be delivered at approximately three-month intervals
throughout 2026 with payment already received for the first 6mt.

·    Record start to 2026 with over £800k of orders received in January
2026 for delivery during 2026 calendar year, including carried forward orders
outlined above (announced 21 January 2026). This excludes ecommerce and
subsequent orders.

·    Strategic shift from building a broad business with holdings in PBX
and SBTX and products in multiple territories to focus on high growth areas
and commercial sustainability

ü Significant reduction in marketing and selling costs during January and
February 2026 of 78% which, with planned reductions in R&D and IP costs,
are anticipated to save £500k-600k per year

ü Margin improvement in cost of goods which should reduce the cost of
producing SlimBiome by 31% in Q2 2026 orders with further changes anticipated
to lead to a final cost reduction of 48%. The Board expects this should
improve gross margin and gross profit

ü The development of profit and loss accounts for each part of its business
(OptiBiotix Health USA, OptiBiotix Health India, Ecommerce and B2B) with each
business unit tasked with covering their costs by end of 2026.  This will
help determine future spending and cost savings

 

The Company has made positive progress in 2025 with growing sales, higher
margins, increased gross profit and valuable assets in its holdings in PBX and
SBTX with a combined market value of circa £6.45m at the end of December
2025. Whilst recent announcements by SBTX have impacted on the current value
of its holding, the Company believes the fundamentals of SBTX's business are
strong.

 

The Company has invested in building a strong portfolio of assets through its
IP, holdings in SBTX and PBX, clinical studies to support health claims, and
an international, manufacturing, distribution and a large e-commerce customer
base through sales and marketing.  This investment is largely complete.  The
Company is now focused on commercial sustainability by increasing sales,
improving margins, reducing costs, and accelerating the commercialisation of
its second-generation products to build revenue streams from both first and
second generation products.

 

With a record sales order book, improving margins, significant cost reductions
underway, and growing promise in second generation products, the Board are
confident that OptiBiotix has the potential to deliver substantial growth in
shareholder value in the years ahead.

 

Stephen O'Hara, CEO of OptiBiotix Health plc said: "The Company has made
strong financial progress in 2025 with growing sales, higher margins,
increased gross profit, holdings valued at £6.45m, and a record start to 2026
sales orders. Having invested in an extensive IP portfolio, health claims for
products in all major markets, an international manufacturing and distribution
base, and a large ecommerce customer base, the Company is now focused on
achieving commercial sustainability by accelerating its activities to reduce
costs and improve margins whilst continuing to grow its top line and
commercialise its second generation products".

 

"As the impact of cost reductions in 2025 have a full year effect and new
initiatives to substantially reduce other costs take place, we move closer to
our aim of achieving profitability across all parts of the business."

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

Engage with the OptiBiotix management team directly by asking questions,
watching video summaries and seeing what other shareholders have to say by
subscribing to the new website to get regular
updates:  https://optibiotix.com/auth/signup
(https://optibiotix.com/auth/signup)

View the full announcement and submit questions to management via our
website:  https://optibiotix.com/link/rDGmLe
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Foptibiotix.com%2Flink%2FrDGmLe&data=05%7C02%7Cspohara%40optibiotix.com%7C3152bd9baa4b4e044eea08de8a5f0a93%7Cfd9d39470fcc410da8d30ce1bec67dce%7C1%7C0%7C639100337949140299%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=bt7V7H0fZ%2BAKJ6UCTqkFj%2FSc18E2j4Sx1bIh8BMtnt0%3D&reserved=0)

 

 For further information, please contact: OptiBiotix Health plc      www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD and Broker)                     Tel: 020 7213 0880
 Liam Murray / Ludovico Lazzaretti / James Western

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has
developed a range of technologies and commercialised products which modulate
the human microbiome to help prevent and manage human disease.  Since the
Group's inception it has created a wide range of microbiome-based ingredients
and products including prebiotic products like SlimBiome®, WellBiome®,
SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc
(OPTI) business, but also skincare through its holdings in SkinBioTherapeutics
PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies
create a diverse portfolio technologies and products in an emerging area of
healthcare that is of growing interest in consumer markets throughout the
world.

Caution regarding forward looking statements

 

Certain statements in this announcement, are, or may be deemed to be,
forward-looking statements. Forward-looking statements are identified by
their use of terms and phrases such as ''believe'', ''could'', "should"
''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'',
"expect", ''will'' or the negative of those, variations or comparable
expressions, including references to assumptions.  These forward-looking
statements are not based on historical facts but rather on the Directors'
current expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof), competitive
advantages, business prospects and opportunities. Such forward-looking
statements reflect the Directors' current beliefs and assumptions and are
based on information currently available to the Directors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTUASBRNWUOOAR



            Copyright 2019 Regulatory News Service, all rights reserved